Olivia S Jew1, Joyce Okawa2, John S Barbieri2, Joanne McCaffrey2, Elizabeth Hayward2, Victoria P Werth3. 1. Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania; Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 2. Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania. 3. Dermatology, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania; Dermatology, CMC VA Medical Center, Philadelphia, Pennsylvania. Electronic address: werth@pennmedicine.upenn.edu.
Abstract
BACKGROUND: In dermatology, prior authorizations can delay treatment, decrease patient adherence, and deter providers from advocating for their patients. Patients with complex dermatologic conditions, often requiring off-label treatments, may face particularly significant insurance barriers. OBJECTIVE: Evaluate the effect of prior authorizations in patients with complex dermatologic conditions. METHODS: This prospective cohort study assessed patients treated by a dermatologist during 5 months who specialized in complex dermatology. Patients included were older than 18 years, treated at V.P.W.'s rheumatology-dermatology clinic, and prescribed a medication or ordered a diagnostic procedure that elicited an insurance prior authorization. Data on prior authorization outcome, administrative time, and delay to treatment were collected. RESULTS: Of 51 prior authorizations, 51% were initially denied, with systemic medications more likely denied than topical ones (P < .001). Total administrative time spent on 50 prior authorizations tracked was 62.5 hours (median time per prior authorization 30 minutes [interquartile range 17-105 minutes]). Time to access treatment was tracked for 80% of prior authorizations; median delay was 12 days [interquartile range 5.5-23 days]. LIMITATIONS: Single-center, single-provider patient panel. CONCLUSION: Patients with complex dermatologic conditions face a significant barrier to care because of prior authorizations. The administrative burden for provider practices to address these prior authorizations is substantial and may warrant a streamlined system in collaboration with insurers.
BACKGROUND: In dermatology, prior authorizations can delay treatment, decrease patient adherence, and deter providers from advocating for their patients. Patients with complex dermatologic conditions, often requiring off-label treatments, may face particularly significant insurance barriers. OBJECTIVE: Evaluate the effect of prior authorizations in patients with complex dermatologic conditions. METHODS: This prospective cohort study assessed patients treated by a dermatologist during 5 months who specialized in complex dermatology. Patients included were older than 18 years, treated at V.P.W.'s rheumatology-dermatology clinic, and prescribed a medication or ordered a diagnostic procedure that elicited an insurance prior authorization. Data on prior authorization outcome, administrative time, and delay to treatment were collected. RESULTS: Of 51 prior authorizations, 51% were initially denied, with systemic medications more likely denied than topical ones (P < .001). Total administrative time spent on 50 prior authorizations tracked was 62.5 hours (median time per prior authorization 30 minutes [interquartile range 17-105 minutes]). Time to access treatment was tracked for 80% of prior authorizations; median delay was 12 days [interquartile range 5.5-23 days]. LIMITATIONS: Single-center, single-provider patient panel. CONCLUSION:Patients with complex dermatologic conditions face a significant barrier to care because of prior authorizations. The administrative burden for provider practices to address these prior authorizations is substantial and may warrant a streamlined system in collaboration with insurers.
Authors: Lawrence P Casalino; Sean Nicholson; David N Gans; Terry Hammons; Dante Morra; Theodore Karrison; Wendy Levinson Journal: Health Aff (Millwood) Date: 2009-05-14 Impact factor: 6.301
Authors: Joerg Albrecht; Mark Lebwohl; Maryam M Asgari; Daniel D Bennett; Ashley Cook; Colby C Evans; Lawrence J Green; Julie A Hodge; Arianne S Kourosh; Mary E Maloney; Leah M Howard; Elise A Olsen; Steven P Rosenberg; Adam Rubin; Dow B Stough; Susan C Taylor; Bruce Alan Brod Journal: J Am Acad Dermatol Date: 2016-07-13 Impact factor: 11.527
Authors: Aaron M Secrest; Maryam M Asgari; Arianne S Kourosh; John S Barbieri; Joerg Albrecht Journal: J Am Acad Dermatol Date: 2017-10 Impact factor: 11.527
Authors: Kira L Ryskina; Erica Goldberg; Briana Lott; Davis Hermann; John S Barbieri; Jules B Lipoff Journal: JAMA Dermatol Date: 2018-04-01 Impact factor: 10.282
Authors: James L Raper; James H Willig; Hui-Yi Lin; Jeroan J Allison; M Bennet Broner; Michael J Mugavero; Michael S Saag Journal: Clin Infect Dis Date: 2010-09-15 Impact factor: 9.079
Authors: Lesley Ann Saketkoo; Tracy Frech; Cecília Varjú; Robyn Domsic; Jessica Farrell; Jessica K Gordon; Carina Mihai; Nora Sandorfi; Lee Shapiro; Janet Poole; Elizabeth R Volkmann; Monika Lammi; Kendra McAnally; Helene Alexanderson; Henrik Pettersson; Faye Hant; Masataka Kuwana; Ami A Shah; Vanessa Smith; Vivien Hsu; Otylia Kowal-Bielecka; Shervin Assassi; Maurizio Cutolo; Cristiane Kayser; Victoria K Shanmugam; Madelon C Vonk; Kim Fligelstone; Nancy Baldwin; Kerri Connolly; Anneliese Ronnow; Beata Toth; Maureen Suave; Sue Farrington; Elana J Bernstein; Leslie J Crofford; László Czirják; Kelly Jensen; Monique Hinchclif; Marie Hudson; Matthew R Lammi; Jennifer Mansour; Nadia D Morgan; Fabian Mendoza; Mandana Nikpour; John Pauling; Gabriela Riemekasten; Anne-Marie Russell; Mary Beth Scholand; Elise Seigart; Tatiana Sofia Rodriguez-Reyna; Laura Hummers; Ulrich Walker; Virginia Steen Journal: Best Pract Res Clin Rheumatol Date: 2021-09-15 Impact factor: 4.991